FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4319005763> ?p ?o ?g. }

• W4319005763 abstract "Introduction: We analyzed data regarding smoking cessation medication use after stroke/TIA in the United States. Methods: We performed a retrospective analysis using data from the Get With The Guidelines®-Stroke registry, which includes data for adult patients receiving acute care for stroke and TIA across the United States. Our outcome of interest was provision of cessation medication (nicotine replacement therapy [NRT], bupropion, varenicline) among patients who were active smokers at the time of stroke/TIA. We used unadjusted and multivariable regression models to explore factors associated with provision of cessation medications. We specifically evaluated whether event type (TIA and hemorrhagic stroke versus ischemic stroke) and burden of smoking-related cardiovascular conditions (≥1 versus 0) were associated with cessation medication provision. Results: Of 1,589,760 patients with stroke/TIA, 187,501 were smokers with available smoking treatment data. The mean age was 59.9 years (SD, 11.6); 42% were women. Most patients (97.7%) received some form of cessation intervention. As for specific treatments, 29.8% were provided cessation medication (NRT: 16.2%; varenicline or bupropion: 13.0%; multiple/other: 2.3%). The remaining 68.5% received counseling alone. In multivariable models, patients with hemorrhagic stroke (OR, 0.81; 95% CI, 0.76-0.86) and TIA (OR, 0.68; 95% CI, 0.64-0.73) had lower odds of receiving cessation medications than ischemic stroke patients. Cardiovascular disease burden was not associated with cessation medication provision (OR, 0.98; 95 CI, 0.94-1.02). However, multivariable models revealed demographic differences. Black (OR, 0.78; 95% CI, 0.74-0.82) and Asian (OR, 0.72; 95% CI, 0.58-0.87) patients had lower odds of receiving cessation medication, compared to White patients. Hispanic ethnicity was also associated with lower odds of cessation medication provision (OR, 0.65; 95% CI, 0.56-0.73). Conclusions: Approximately 30% of smokers were provided a smoking cessation medication during hospitalization. Compared to ischemic stroke, TIA and hemorrhagic stroke were associated with lower rates of smoking cessation medication provision, and racial and ethnic disparities were identified." @default.
• W4319005763 created "2023-02-03" @default.
• W4319005763 creator A5017671912 @default.
• W4319005763 creator A5042731343 @default.
• W4319005763 creator A5056408846 @default.
• W4319005763 creator A5064975333 @default.
• W4319005763 creator A5082538548 @default.
• W4319005763 creator A5085675203 @default.
• W4319005763 creator A5088527297 @default.
• W4319005763 date "2023-02-01" @default.
• W4319005763 modified "2023-09-23" @default.
• W4319005763 title "Abstract WMP40: Patterns And Predictors Of Smoking Cessation Pharmacotherapy Provision After Stroke And Transient Ischemic Attack: Findings From The Get With The Guidelines-Stroke Registry" @default.
• W4319005763 doi "https://doi.org/10.1161/str.54.suppl_1.wmp40" @default.
• W4319005763 hasPublicationYear "2023" @default.
• W4319005763 type Work @default.
• W4319005763 citedByCount "0" @default.
• W4319005763 crossrefType "journal-article" @default.
• W4319005763 hasAuthorship W4319005763A5017671912 @default.
• W4319005763 hasAuthorship W4319005763A5042731343 @default.
• W4319005763 hasAuthorship W4319005763A5056408846 @default.
• W4319005763 hasAuthorship W4319005763A5064975333 @default.
• W4319005763 hasAuthorship W4319005763A5082538548 @default.
• W4319005763 hasAuthorship W4319005763A5085675203 @default.
• W4319005763 hasAuthorship W4319005763A5088527297 @default.
• W4319005763 hasConcept C126322002 @default.
• W4319005763 hasConcept C127413603 @default.
• W4319005763 hasConcept C142724271 @default.
• W4319005763 hasConcept C156957248 @default.
• W4319005763 hasConcept C167135981 @default.
• W4319005763 hasConcept C1862650 @default.
• W4319005763 hasConcept C194828623 @default.
• W4319005763 hasConcept C2777053506 @default.
• W4319005763 hasConcept C2777843972 @default.
• W4319005763 hasConcept C2779908668 @default.
• W4319005763 hasConcept C2780645631 @default.
• W4319005763 hasConcept C500440147 @default.
• W4319005763 hasConcept C71924100 @default.
• W4319005763 hasConcept C78519656 @default.
• W4319005763 hasConceptScore W4319005763C126322002 @default.
• W4319005763 hasConceptScore W4319005763C127413603 @default.
• W4319005763 hasConceptScore W4319005763C142724271 @default.
• W4319005763 hasConceptScore W4319005763C156957248 @default.
• W4319005763 hasConceptScore W4319005763C167135981 @default.
• W4319005763 hasConceptScore W4319005763C1862650 @default.
• W4319005763 hasConceptScore W4319005763C194828623 @default.
• W4319005763 hasConceptScore W4319005763C2777053506 @default.
• W4319005763 hasConceptScore W4319005763C2777843972 @default.
• W4319005763 hasConceptScore W4319005763C2779908668 @default.
• W4319005763 hasConceptScore W4319005763C2780645631 @default.
• W4319005763 hasConceptScore W4319005763C500440147 @default.
• W4319005763 hasConceptScore W4319005763C71924100 @default.
• W4319005763 hasConceptScore W4319005763C78519656 @default.
• W4319005763 hasIssue "Suppl_1" @default.
• W4319005763 hasLocation W43190057631 @default.
• W4319005763 hasOpenAccess W4319005763 @default.
• W4319005763 hasPrimaryLocation W43190057631 @default.
• W4319005763 hasRelatedWork W1778717419 @default.
• W4319005763 hasRelatedWork W1843977356 @default.
• W4319005763 hasRelatedWork W1964739340 @default.
• W4319005763 hasRelatedWork W2024362416 @default.
• W4319005763 hasRelatedWork W2051592059 @default.
• W4319005763 hasRelatedWork W2293248869 @default.
• W4319005763 hasRelatedWork W2324506369 @default.
• W4319005763 hasRelatedWork W3157686039 @default.
• W4319005763 hasRelatedWork W2100771608 @default.
• W4319005763 hasRelatedWork W2625883319 @default.
• W4319005763 hasVolume "54" @default.
• W4319005763 isParatext "false" @default.
• W4319005763 isRetracted "false" @default.
• W4319005763 workType "article" @default.